AGIOS PHARMACEUTICALS, INC. Research and Development Arrangement, Contract to Perform for Others, Compensation Earned
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Research and Development Arrangement, Contract to Perform for Others, Compensation Earned of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-19.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned · last filed 2020-02-19
- AGIOS PHARMACEUTICALS, INC. research and development arrangement, contract to perform for others, compensation earned for the quarter ending 2018-12-31 was $0.00, a 100.00% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. research and development arrangement, contract to perform for others, compensation earned for the quarter ending 2018-09-30 was $0.00, a 100.00% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. research and development arrangement, contract to perform for others, compensation earned for the quarter ending 2018-06-30 was $0.00, a 100.00% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. research and development arrangement, contract to perform for others, compensation earned for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. research and development arrangement, contract to perform for others, compensation earned for fiscal 2019 was $0.00.
- AGIOS PHARMACEUTICALS, INC. research and development arrangement, contract to perform for others, compensation earned for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- AGIOS PHARMACEUTICALS, INC. research and development arrangement, contract to perform for others, compensation earned for fiscal 2017 was $7.81M, a 60.38% decline from fiscal 2016.
- AGIOS PHARMACEUTICALS, INC. research and development arrangement, contract to perform for others, compensation earned for fiscal 2016 was $19.71M, a 21.69% decline from fiscal 2015.
| Period end | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 3 month | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 6 month | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 9 month | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-02-19 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $0.00 derived: sum of 2 quarters · filed 2020-02-19 | $0.00 derived: sum of 3 quarters · filed 2020-02-19 | $0.00 10-K · filed 2020-02-19 |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-01 | $0.00 derived: sum of 2 quarters · filed 2018-11-01 | $0.00 10-Q · filed 2018-11-01 | $1.47M derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-02 | $0.00 10-Q · filed 2018-08-02 | $1.47M derived: sum of 3 quarters · filed 2020-02-19 | $2.55M derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-04 | $1.47M derived: sum of 2 quarters · filed 2020-02-19 | $2.55M derived: sum of 3 quarters · filed 2020-02-19 | $5.04M derived: sum of 4 quarters · filed 2020-02-19 |
| 2017-12-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $2.55M derived: sum of 2 quarters · filed 2020-02-19 | $5.04M derived: sum of 3 quarters · filed 2020-02-19 | $7.81M 10-K · filed 2020-02-19 |
| 2017-09-30 | $1.08M 10-Q · filed 2018-11-01 | $3.57M derived: sum of 2 quarters · filed 2018-11-01 | $6.34M 10-Q · filed 2018-11-01 | $7.30M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-06-30 | $2.49M 10-Q · filed 2018-08-02 | $5.26M 10-Q · filed 2018-08-02 | $6.22M derived: sum of 3 quarters · filed 2019-02-14 | $10.26M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-03-31 | $2.78M 10-Q · filed 2018-05-04 | $3.74M derived: sum of 2 quarters · filed 2019-02-14 | $7.77M derived: sum of 3 quarters · filed 2019-02-14 | $13.70M derived: sum of 4 quarters · filed 2019-02-14 |
| 2016-12-31 | $960.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | $5.00M derived: sum of 2 quarters · filed 2019-02-14 | $10.92M derived: sum of 3 quarters · filed 2019-02-14 | $19.71M 10-K · filed 2019-02-14 |
| 2016-09-30 | $4.04M 10-Q · filed 2017-11-01 | $9.96M derived: sum of 2 quarters · filed 2017-11-01 | $18.75M 10-Q · filed 2017-11-01 | |
| 2016-06-30 | $5.92M 10-Q · filed 2017-08-08 | $14.72M 10-Q · filed 2017-08-08 | ||
| 2015-12-31 | $25.17M 10-K · filed 2018-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |